David Gardner has touted and teased many stocks for both his Rule Breakers and his Stock Advisor services — probably, in fact, we’ve covered more Motley Fool teaser ads here at Stock Gumshoe than we have any other publisher (and according to the quick calculations of one of our readers, they’ve had more winners than […]
Articles
- Most Relevant
- Most Recent
We see pitches about the “end of money” all the time — across the spectrum from the goofy spiel for “loyalty points” being the next Bitcoin, to actually trading in Bitcoin, to the more popular “end of America” pitch about the dollar dying and the need to have old silver coins and gold in your […]
Alzheimer’s Disease: Current Options and Possible Treatment Approaches[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes about health and medicine for us from time to time. His columns are not generally focused on investments, though this one does include some commentary about a number of specific companies (most are not publicly traded). His words and opinions are his own, […]
“This rare private deal could score you up to 3,000% returns over time — or more!” That’s the attention-getting intro to the latest ad from Jim Rickards, who now has yet another paid newsletter service with Agora Financial — this one that he’s selling today is called Jim Rickards’ Private Dealflow, and it seems to […]
Taking down Pfizer — hasn’t that already been done? At least, if you think a drop of 60% or so in share price over five years for a “blue chip” company is a “takedown.” But that’s the promise of a recent issue of the Penny Sleuth free email newsletter — and to find the details […]
Alzheimer’s Disease always gets a lot of attention from newsletter publishers, readers and investors — not only because we all know someone who suffers from this terrible malady, but because we know that the current treatments are ineffective and the market is huge… which means that any real solutions or more effective treatments could create […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
Another day, another promise of imminent riches from a biotech clinical trial! This time it’s from Ray Blanco, who has made many such promises in his ads, and the pitch is all about a “bio switch” that has the potential to “end diabetes, plus heart & kidney disease (with a twice-a-day pill).” What more could […]
If newsletter guys know anything, it’s how to sell gold investments — gold has been at the core of the newsletter hype industry since the 1980s, attracting ornery gold bugs every time the gold price rises a bit, so we’re seeing most publishers running quickly to the virtual mailbox with their gold pitches these days… […]
Gobble Gobble! It’s that time again! Stock Gumshoe is mostly closed down for the holiday week, but we do have to continue our annual tradition of calling out our “Turkey of the Year” … so take a pause from that turkey brining and join us, won’t you? What is this tradition, you ask? Every year, […]
The last time we were inundated with a junior mining promo from Nick Hodge it was about that “tiny 50 cent mine” that was about to get the “green light” from Trump’s EPA, and that one has done quite well so far — that was Midas Gold, which I wrote about back when they started […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
“Move over Geron, Genentech and Osiris… The next generation in revolutionary biotechs has arrived. “(And they may be the only way to make money in this market!) “Each one of these 3 breakout stocks could realistically bring you gains of 128%, 185%, or even 422% in the next 6 months!” That heady promise introduces an […]
Today I decided to sit down for a while with a teaser ad from Dr. Mark Skousen’s Forecasts & Strategies ($50/year) — this letter is actually from his publisher, Roger Michalski, but it focuses on an idea of Skousen’s that he calls “American X”. So what is this secret “American X” company? It’s apparently got […]
We’ve seen quite a few ads from Jim Pearce at Personal Finance about his favorite “self driving cars” idea, so it’s time to feed the Thinkolator and get some answers for you, dear Gumshoe readers. The basic backdrop for this is, of course, pretty well known — cars are becoming smarter and smarter, self-driving cars […]
This teaser is going to get a lot of attention from Gumshoe readers, partly because Stansberry Phase 1 Investor teasers always get a lot of attention (they usually tease a small stock and they charge $5,000 for the newsletter, which gives them an aura of awesomeness — deserved or not), and partly because the pitch […]
The folks at Phase 1 Investor, the “big ticket” newsletter from Stansberry & Associates currently helmed by Frank Curzio, tend to love teensy weensy biotech and mining stocks — so when the teaser from Curzio hit my inbox this week for a more traditional tech stock with a more reasonable market cap, I sat up […]
Gerardo Del Real is peppering us with pitches for his Junior Resource Speculator ($1,999/yr, 60-day refund period), and the core of that pitch is that we’re in the early stages of a commodity price supercycle, with lots of different natural resources poised to soar… which then leads into a pitch for his three favorite 1,000%-gain […]
This article was originally published in February, the ad is recirculating with minor updates (mostly that the “deadline” is now April 1, versus previous versions that cited January 1 or February 1), so we’re re-sharing this piece to help answer continuing reader questions. What appears below has not been updated since 2/7/18. I’m sure quite […]
Braden Copeland used to work for Porter Stansberry, co-editing his Stansberry’s Investment Advisory and working on Inside Strategist (since shuttered) that picked stocks based on insider buying. Earlier this year, he moved down the street to a different Agora-affiliated office to work for Bill Bonner’s son, Will, at Bonner & Partners and launch a newsletter […]
I’m going to get to several updates on Real Money Portfolio stocks at the end, including those questions “What to do with Qualcomm (QCOM)?” … but first, I’m going to go through the stocks where I’ve completed my Annual Review this week. Each year I promise to re-analyze and reconsider my opinion about each stock […]
$10 Casino King – Dent – probably solved – Opinion of teased company? Dent – Hidden Profits John Del Vecchio What company is being teased? – lots of clues – Think I’m right? http://bit.ly/CasinoTease If you move quickly, you have the chance to make more than $100,000 off a single investment. You see, by voting […]
This is an odd one, so be forewarned. A bunch of readers jumped in to ask me about emails coming out of Investorplace that pitch a tiny private company heading into FDA approval as the focus of their “Blockbuster FDA Approval Summit 2019” presentation… and yes, of course, the Mighty, Mighty Thinkolator can tell you […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
for the best returns on investment for this industry? Thanks Travis!
The response was pretty overwhelmingly positive when I started sending out those “Trade Note” emails this week… so I’ll stick with it for a while, at least, and see how this goes. What does that mean? Same day buy/sell notes about my Real Money Portfolio will be sent to the Irregulars going forward, in hopes […]
Ever since I started Stock Gumshoe as a little “nights and weekends” project back in the Spring of 2008, we’ve made an effort to “give back” in some substantial way — we’ve given to a dozen or so different charities over the years, and every year we’ve set a new record for how much we […]
This article originally ran on October 25, the ad is again circulating in slightly different form and sending a lot of questions our way, so we’re re-publishing it here for you today… the basic spiel and the stock are still the same, though they’re being used to pitch a different newsletter. The stock has bumped […]
Gobble Gobble! It’s that time again! Stock Gumshoe is mostly closed down for the holiday week, but we do have to continue our annual tradition of calling out our “Turkey of the Year” … so take a pause from that turkey brining and join us, won’t you? What is this tradition, you ask? Every year, […]
Nick Hodge has been touting “next big thing” materials stocks for as long as Stock Gumshoe has been around, from rare earth magnets to graphite and uranium and lithium and cobalt and pretty much any other heavily-hyped stuff you might imagine digging out of the ground… and his latest pitch is about what is arguably […]
There was an election on Tuesday, I hear. I voted. The counting is almost over now. Apparently the world did not end, and now we begin the campaign for the next election… everyone raise their hand who wants to vote for austerity and deficit reduction and lower spending and higher taxes and delayed Social Security […]
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
what is the name and ticker for the Wyoming uranium stock Gerardo Del Rio is pushing?
Ray Blanco seems to love pitching a good “results coming soon” story for his FDA Trader ($1,495, no refunds) newsletter over at Agora, and this one is no different from dozens of others he has touted in the past… though the stock is one I haven’t seen him tease before. OK, fine, yes, I know […]
This ad has been rolling around here at Stock Gumshoe, but I haven’t had a chance to look at it until today… and a few new readers asked about it just recently, so I’m taking my chance now… with the caveat that I last saw the ad circulated about a month ago, so I can’t […]
Entry level newsletter with the stated aim of “uncovering the stocks that pay you first,” with a focus on dividends, buybacks and paying down debt. This publication has been closed.
Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]
For those of us who live in this part of the country and spend any time messing around outdoors in the grass and weeds, this is the time to be careful about Lyme disease. I had a bout of Lyme 16 years ago, and it descended on me when we were on vacation, driving through […]
If so, I would imagine huge implications. Here is the pitch: https://pro.agorafinancial.com/p/awn_sdrblockchainv2_0418/MAWNU904/Full?a=10&o=36838&s=74950&u=1008055&l=670821&r=MC2&vid=lJTEu_&g=0&h=true
This article was originally published as part of the Friday File on August 10, 2018. It has not been updated or revised, though the stock teased is still at roughly the same price and no major news has hit since then. We’re breaking the Friday File up into two parts today — starting with this […]